PEG-IFN-α-2a therapy in patients with myelofibrosis: A study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM): Correspondence

British Journal of Haematology

Volumn 146, Issue 2, 2009, Pages 223-225

  Ianotto, Jean Christophe ^a   Kiladjian, Jean Jacques ^b   Demory, Jean Louis ^c   Roy, Lydia ^d   Boyer, Françoise ^e   Rey, Jerôme ^f   Dupriez, Brigitte ^g   Berthou, Christian ^a   Abgrall, Jean François ^h  

^a CHU MORVAN   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c Groupement Hospitalier de l'Institut Catholique   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g Service d'Hematologie Clinique   (France)

^h SERVICE DE RHUMATOLOGIE   (France)

Author keywords

European Myelofibrosis Network; Myelofibrosis; Pegylated interferon; Response criteria; Treatment

Indexed keywords

ANAGRELIDE; HYDROXYUREA; MERCAPTOPURINE; PEGINTERFERON ALPHA2A;

ADULT; AGED; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FRANCE; HUMAN; LETTER; LEUKOCYTE COUNT; MALE; MYELOFIBROSIS; PRIORITY JOURNAL; SPLENOMEGALY; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HEMATOLOGIC AGENTS; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PRIMARY MYELOFIBROSIS;

EID: 67649976491     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07745.x     Document Type: Letter

References (8)

1. Barosi, G., Bordessoule, D., Briere, J., Cervantes, F., Demory, J.L., Dupriez, B., Gisslinger, H., Griesshammer, M., Hasselbalch, H., Kusec, R., Le Bousse-Kerdiles, M.C., Liberato, N.L., Marchetti, M., Reilly, J.T. Thiele, J., European Myelofibrosis Network (2005) Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood, 106, 2849 2853. (Pubitemid 41510763)
2. Hasselbalch, H.C. (2009) Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment? Leukemia Research, 33, 11 18.
3. Jabbour, E., Kantarjian, H., Cortes, J., Thomas, D., Garcia-Manero, G., Ferrajoli, A., Faderi, S., Richie, M.A., Beran, M., Giles, F. Vertovsek, S. (2007) PEG-IFN-α-2b therapy in BCR-ABL-negative myeloproliferative disorders. Cancer, 110, 2012 2018.
4. Kiladjian, J.J., Chomienne, C. Fenaux, P. (2008a) Interferon-α therapy in bcr-abl-negative myeloproliferative neoplasms. Leukemia, 22, 1990 1998.
5. Kiladjian, J.J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, N., Bellucci, S., Grandchamp, B., Chomienne, C. Fenaux, P. (2008b) Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 112, 3065 3072.
6. Kröger, N. Mesa, R.A. (2008) Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia, 22, 474 486.
7. Parmeggiani, L., Ferrant, A., Rodhain, J., Michaux, J.L. Sokal, G. (1987) Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia. European Journal of Haematology, 39, 228 232. (Pubitemid 17133321)
8. Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., Reilly, J.T., Gisslinger, H., Vannucchi, A.M., Cervantes, F., Finazzi, G., Hoffman, R., Gilliland, D.G., Bloomfield, C.D. Vardiman, J.W. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 110, 1092 1097. (Pubitemid 47281402)